Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
37657247 2023 Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer. International immunopharmacology Likely relevant The study experimentally analyzes single-cell transcriptome data from NSCLC patients treated with anti-PD-1 therapy, measuring immune cell subtypes and immune-related processes. anti-PD-1 Patient non-small-cell lung cancer anti-PD-1 14/36/0 Awaiting curator check
37731001 2023 The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature Likely relevant The study tests beta-blockers and immune checkpoint blockade in animal tumor models and evaluates effects on CD8+ T cell responses and exhaustion. immune checkpoint blockade; beta-blockers Animal melanoma and pancreatic cancer immune checkpoint blockade 0/1/0; beta-blockers 0/0/0 Awaiting curator check
37749092 2023 THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. Nature communications Likely relevant The study uses orthotopically generated CRC mouse models to evaluate the effect of THBS1 loss combined with immune checkpoint inhibitors and anti-cancer drugs on T-cell exhaustion and antitumor immunity. immune checkpoint inhibitors; anti-cancer drugs Animal colorectal cancer immune checkpoint inhibitors 0/0/0; anti-cancer drugs 0/0/0 Awaiting curator check
37752135 2023 PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models. Nature communications Likely relevant The study experimentally tests a PARP14 inhibitor and anti-PD-1 therapy in mouse tumor models, measuring effector T cell and regulatory T cell infiltration. alpha-PD-1; PARP14 inhibitor Animal melanoma and other syngeneic mouse tumor models alpha-PD-1 0/0/0; PARP14 inhibitor 0/0/0 Awaiting curator check
37776054 2023 Intratumoral administration of unconjugated Accum™ impairs the growth of pre-established solid lymphoma tumors. Cancer science Likely relevant Tests unconjugated Accum alone and with immune checkpoint inhibitors in cell lines and lymphoma-bearing animals, measuring ROS, immunogenic cell death, and T cell involvement. Accum; anti-CTLA4; anti-PD-1; anti-CD47 Mixed lymphoma Accum 0/0/0; anti-CTLA4 0/0/0; anti-PD-1 14/36/0; anti-CD47 0/0/0 Awaiting curator check
37777506 2023 STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal transduction and targeted therapy Likely relevant The study investigates the effect of immune checkpoint inhibitors on reactive CD8+ T cells when co-cultured with AML cells exhibiting STAT5-induced glycolysis and PD-L1 expression. immune checkpoint inhibitor; PD-1/PD-L1 blocker Cell line acute myeloid leukemia immune checkpoint inhibitor 0/0/0; PD-1/PD-L1 blocker 0/0/0 Awaiting curator check
37794185 2023 The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature Likely relevant The study experimentally tests the PTPN2 and PTPN1 inhibitor ABBV-CLS-484 in vitro and in mouse models, measuring its effects on immune cell activation, NK and CD8+ T cell function, and the tumor microenvironment. ABBV-CLS-484; PD-1 blockade Mixed advanced solid tumours ABBV-CLS-484 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
37865045 2023 The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors. EBioMedicine Likely relevant Tests immunotherapy combined with a microbial metabolite in mice and measures T cell and NK cell activation. anti-CTLA-4; anti-PD-1 Animal cancer anti-CTLA-4 1/10/7; anti-PD-1 14/36/0 Awaiting curator check
37880183 2023 MCT4 blockade increases the efficacy of immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant The study tests MCT inhibitors and anti-PD-L1 in vitro and in vivo, and measures immune cell infiltration, T-cell function and activation. AZD3965; MCT4 inhibitor; anti-PD-L1 Mixed colorectal carcinoma AZD3965 0/0/0; MCT4 inhibitor 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
33692094 2022 Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut Likely relevant The study tests an anti-WNT2 monoclonal antibody and anti-PD-1 in mouse models and measures their effects on dendritic cell differentiation and antitumour T-cell responses. anti-WNT2 monoclonal antibody; anti-programmed cell death protein 1 (PD-1) Animal oesophageal squamous cell carcinoma and colorectal cancer anti-WNT2 monoclonal antibody 0/0/0; anti-programmed cell death protein 1 (PD-1) 0/0/0 Awaiting curator check
34160685 2022 T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. Cancer immunology, immunotherapy : CII Likely relevant The study tests ICIs combined with cyclophosphamide or axitinib in mice and evaluates T-cell infiltration and responses. anti-PD-1; anti-CTLA-4; cyclophosphamide; axitinib Animal renal cell carcinoma anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; cyclophosphamide 5/15/9; axitinib 5/7/0 Awaiting curator check
34253574 2022 Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut Likely relevant The study investigates the impact of Helicobacter pylori infection on the efficacy and immune readouts of checkpoint inhibitors and cancer vaccines in mouse models and human cohorts. anti-CTLA-4; anti-PD-L1; anti-PD-1 Mixed colon adenocarcinoma and melanoma anti-CTLA-4 1/10/7; anti-PD-L1 0/15/0; anti-PD-1 14/36/0 Awaiting curator check
34278517 2022 Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer immunology, immunotherapy : CII Likely relevant The study evaluates lung cancer patients treated with PD-1/PD-L1 inhibitors and measures the effect on circulating regulatory T cells. PD-1/PD-L1 inhibitors Patient lung cancer PD-1/PD-L1 inhibitors 0/0/0 Awaiting curator check
34349241 2022 Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer gene therapy Likely relevant The study experimentally tests gene therapy combined with immune checkpoint inhibitors and agonists in an animal tumor model and measures changes in gene expression profiles related to immune signatures. adenoviral p53; anti-PD-1; IL2 or IL15 CD122/132 agonists Animal melanoma adenoviral p53 0/0/0; anti-PD-1 14/36/0; IL2 or IL15 CD122/132 agonists 0/0/0 Awaiting curator check
34774916 2022 The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Immunology letters Likely relevant The study tests an oncolytic virus combined with pembrolizumab in mice and measures immune cell infiltration, cytokine secretion, and PD-L1 expression. VT09X; pembrolizumab Animal melanoma VT09X 0/0/0; pembrolizumab 0/0/16 Awaiting curator check
34825915 2022 WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. The Journal of experimental medicine Likely relevant The study tests a WEE1 inhibitor combined with PD-L1 blockade in tumor models, measuring ERV expression, dsRNA pathway activation, interferon response, and CD8+ T cell recruitment. WEE1 inhibitor; PD-L1 blockade Animal tumor models WEE1 inhibitor 0/0/0; PD-L1 blockade 0/4/0 Awaiting curator check
34898004 2022 Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO molecular medicine Likely relevant Tests Carfilzomib in high-throughput assays and a transgenic mouse model, measuring macrophage reprogramming, cytokine expression, and antigen presentation. Carfilzomib; PD-1 antibody Mixed lung cancer Carfilzomib 0/0/0; PD-1 antibody 0/3/0 Awaiting curator check
34981670 2022 Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer communications (London, England) Likely relevant The study experimentally tests anti-PD-1 antibodies and the anti-PD-L1/TGF-betaR fusion protein SHR-1701 in lung cancer models and patients, measuring immune cell subsets and functions. SHR-1701; anti-PD-1 antibodies Mixed lung cancer SHR-1701 0/0/0; anti-PD-1 antibodies 0/0/0 Awaiting curator check
35122074 2022 Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nature cancer Likely relevant The study experimentally tests trametinib and nintedanib in combination, and evaluates their effect on tumor microenvironment remodeling and T cell infiltration. trametinib; nintedanib; anti-PD-L1 Mixed pancreatic ductal adenocarcinoma trametinib 59/33/6; nintedanib 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
35132961 2022 Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI insight Likely relevant Tests anti-PD-L1 and anti-CD73 antibodies in cell lines and xenograft mouse models, measuring T cell killing, proliferation, infiltration, and cytokine production. anti-PD-L1; anti-CD73 Mixed non-small cell lung cancer anti-PD-L1 0/15/0; anti-CD73 0/0/0 Awaiting curator check
35145222 2022 Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. Nature cell biology Likely relevant The study tests anti-PD-1 immune checkpoint blockade therapy in mouse models and evaluates its effects on CD8+ T cell intratumoural infiltration. anti-PD-1 Animal cancer anti-PD-1 14/36/0 Awaiting curator check
35236758 2022 Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life science alliance Likely relevant The study tests immune checkpoint blockade therapy in mouse syngeneic tumor models and correlates Meflin-positive CAFs with CD4-positive T-cell infiltration. immune checkpoint blockade Animal non-small cell lung cancer immune checkpoint blockade 0/1/0 Awaiting curator check
35241835 2022 The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nature cancer Likely relevant The study investigates the role of Tht cells and their interaction with dendritic cells in harnessing the antitumor response of anti-PD-1 treatment using in vitro and mouse models. anti-PD-1 Mixed non-small cell lung carcinoma anti-PD-1 14/36/0 Awaiting curator check
35254416 2022 Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer discovery Likely relevant The study experimentally tests a novel small-molecule PD-L1 inhibitor (INCB086550) in vitro, in humanized mice, and in patients, and measures its effects on immune cell cytokine production, T-cell activation, and gene signatures. INCB086550 Mixed unspecified INCB086550 0/0/0 Awaiting curator check
35278076 2022 Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. The oncologist Likely relevant The study experimentally tests interferon gamma treatment on NSCLC and thoracic fibroblast cell lines and measures CXCL9 and PD-L1 expression. interferon gamma Mixed thoracic SMARCA4-deficient undifferentiated tumors, non-small cell lung cancer interferon gamma 0/0/0 Awaiting curator check
← Previous Page 11 of 15 Next →